Gonzalez-Cao, MariaKarachaliou, NikiSantarpia, MariacarmelaViteri, SantiagoMeyerhans, AndreasRosell, Rafael2022-10-252022-10-252018Gonzalez-Cao M, Karachaliou N, Santarpia M, Viteri S, Meyerhans A, Rosell R. Activation of viral defense signaling in cancer. Ther Adv Med Oncol. 2018 Jan-Dec;10:1–12. DOI: 10.1177/17588359187931051758-8340http://hdl.handle.net/10230/54560A coordinated action of innate and adaptive immune responses is required to efficiently combat a microbial infection. It has now become clear that cancer therapies also largely benefit when both arms of the immune response are engaged. In this review, we will briefly describe the current knowledge of innate immunity and how this can be utilized to prime tumors for a better response to immune checkpoint inhibitors. Comments on compounds in development and ongoing clinical trials will be provided.application/pdfeng© The Author(s), 2018. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).info:eu-repo/semantics/articlehttp://dx.doi.org/10.1177/1758835918793105Cancer immunotherapyInnate immunityTLRsViral defense signalinginfo:eu-repo/semantics/openAccess